Analysts forecast that Audentes Therapeutics Inc (NASDAQ:BOLD) will report ($0.90) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Audentes Therapeutics’ earnings. The lowest EPS estimate is ($1.03) and the highest is ($0.87). Audentes Therapeutics posted earnings per share of ($0.74) in the same quarter last year, which indicates a negative year over year growth rate of 21.6%. The firm is expected to report its next quarterly earnings report on Wednesday, May 8th.
According to Zacks, analysts expect that Audentes Therapeutics will report full-year earnings of ($3.80) per share for the current year, with EPS estimates ranging from ($4.46) to ($3.47). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.66) per share, with EPS estimates ranging from ($4.21) to ($2.51). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Audentes Therapeutics.
Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.84) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.92) by $0.08. During the same period last year, the firm posted ($0.82) earnings per share.
Audentes Therapeutics stock traded down $0.54 during mid-day trading on Wednesday, reaching $40.46. The stock had a trading volume of 1,394 shares, compared to its average volume of 477,942. Audentes Therapeutics has a fifty-two week low of $17.95 and a fifty-two week high of $46.18. The stock has a market capitalization of $1.75 billion, a PE ratio of -11.90 and a beta of 1.96.
In related news, VP Suyash Prasad sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $30.06, for a total value of $300,600.00. Following the transaction, the vice president now directly owns 28,236 shares of the company’s stock, valued at approximately $848,774.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Matthew R. Patterson sold 21,000 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $30.00, for a total value of $630,000.00. Following the completion of the transaction, the chief executive officer now directly owns 135,700 shares in the company, valued at $4,071,000. The disclosure for this sale can be found here. Insiders sold a total of 51,000 shares of company stock worth $1,650,600 over the last ninety days. 6.60% of the stock is currently owned by insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Partner Fund Management L.P. raised its position in shares of Audentes Therapeutics by 94.4% in the fourth quarter. Partner Fund Management L.P. now owns 3,021,259 shares of the biotechnology company’s stock worth $64,413,000 after acquiring an additional 1,467,120 shares during the period. BlackRock Inc. increased its position in shares of Audentes Therapeutics by 15.8% during the 4th quarter. BlackRock Inc. now owns 2,974,591 shares of the biotechnology company’s stock worth $63,418,000 after purchasing an additional 406,605 shares during the last quarter. Great Point Partners LLC acquired a new position in shares of Audentes Therapeutics during the 4th quarter worth approximately $35,346,000. Vanguard Group Inc increased its position in shares of Audentes Therapeutics by 1.9% during the 3rd quarter. Vanguard Group Inc now owns 1,342,931 shares of the biotechnology company’s stock worth $53,166,000 after purchasing an additional 24,585 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Audentes Therapeutics by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,342,931 shares of the biotechnology company’s stock worth $53,166,000 after purchasing an additional 24,585 shares during the last quarter.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Story: Cost of Debt
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.